Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are now key agents in treating EGFR-mutant non-small cell lung cancer (NSCLC). The efficacy of gefitinib or erlotinib monotherapy can be predicted by the development of a skin rash. However, it has not been fully eval...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2016-05, Vol.77 (5), p.1005-1009 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1009 |
|---|---|
| container_issue | 5 |
| container_start_page | 1005 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 77 |
| creator | Kudo, Kenichiro Hotta, Katsuyuki Bessho, Akihiro Nogami, Naoyuki Kozuki, Toshiyuki Kuyama, Shoichi Inoue, Koji Harita, Shingo Okada, Toshiaki Gemba, Kenichi Fujii, Masanori Takigawa, Nagio Oda, Naohiro Tanimoto, Mitsune Kiura, Katsuyuki |
| description | Background
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are now key agents in treating EGFR-mutant non-small cell lung cancer (NSCLC). The efficacy of gefitinib or erlotinib monotherapy can be predicted by the development of a skin rash. However, it has not been fully evaluated if this is the case with afatinib monotherapy.
Methods
We retrospectively studied 49 consecutive patients with EGFR-mutant NSCLC who received afatinib therapy between 2009 and 2015. The relationship of several toxicities with tumor response was examined.
Results
Grade 2, or more severe, common adverse events (AEs) included skin rash in 17 patients (35 %), diarrhea in 19 (39 %) and mucositis in 15 (31 %). Of these, the number of patients who developed ≥Grade 2 AEs during the first week after the initiation of afatinib therapy was: five patients had skin rash (10 %), 12 patients had diarrhea (25 %) and four patients had mucositis (8 %). As for an objective response, 21 (43 %) of the 49 had a partial response. Associating the AEs with the antitumor effect, those who had a ≥Grade 2 skin rash within the first week tended to have a greater tumor response compared with those without a rash (80 vs. 39 %;
p
= 0.077).
Conclusion
Our small study demonstrated that the early development of a skin rash might be associated with the response to afatinib monotherapy. |
| doi_str_mv | 10.1007/s00280-015-2910-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1784028343</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4034495621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-92c5da80e5fcd698ca6727222385193ffc46222170e272006a340d99be76bcb63</originalsourceid><addsrcrecordid>eNp1UU1v1DAUtBCIbgs_gAuyxAUOhuePfHFDoV2QVlSicI4c57mb7sZJbYeyf6-_DC8piAsH288z82YOQ8gLDm85QPEuAIgSGPCMiYoDqx6RFVdSMCiVfExWIJViWQHqhJyGcAMAikv5lJyIAkSVC7ki9x_xB-7HaUAX6WippmHXO-p12NK7Pm7THLdIbe9DpHeIO6pd9xtKx-sJ59gbitaiiTSJtdWxd31Lh9GNi-RA7ejp-friKxvmqFOOGx0Lg97vqcF07Wd3TY12Bj19_eWq3tRv3tPLnT7oQdPNkawX8irO3YGu_ThPFH9O6HtM-DPyxOp9wOcP7xn5fnH-rf7ENpfrz_WHDTNKlpFVwmSdLgEza7q8Ko3OC1EIIWSZ8Upaa1SefrwATDBArqWCrqpaLPLWtLk8I68W38mPtzOG2NyMs3cpsuFFqVIVUsmk4ovK-DEEj7aZfD9of2g4NMfWmqW1JrXWHFtrqrTz8sF5bgfs_m78qSkJxCIIiXLX6P-J_q_rLwJ4o2c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1784028343</pqid></control><display><type>article</type><title>Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Kudo, Kenichiro ; Hotta, Katsuyuki ; Bessho, Akihiro ; Nogami, Naoyuki ; Kozuki, Toshiyuki ; Kuyama, Shoichi ; Inoue, Koji ; Harita, Shingo ; Okada, Toshiaki ; Gemba, Kenichi ; Fujii, Masanori ; Takigawa, Nagio ; Oda, Naohiro ; Tanimoto, Mitsune ; Kiura, Katsuyuki</creator><creatorcontrib>Kudo, Kenichiro ; Hotta, Katsuyuki ; Bessho, Akihiro ; Nogami, Naoyuki ; Kozuki, Toshiyuki ; Kuyama, Shoichi ; Inoue, Koji ; Harita, Shingo ; Okada, Toshiaki ; Gemba, Kenichi ; Fujii, Masanori ; Takigawa, Nagio ; Oda, Naohiro ; Tanimoto, Mitsune ; Kiura, Katsuyuki</creatorcontrib><description>Background
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are now key agents in treating EGFR-mutant non-small cell lung cancer (NSCLC). The efficacy of gefitinib or erlotinib monotherapy can be predicted by the development of a skin rash. However, it has not been fully evaluated if this is the case with afatinib monotherapy.
Methods
We retrospectively studied 49 consecutive patients with EGFR-mutant NSCLC who received afatinib therapy between 2009 and 2015. The relationship of several toxicities with tumor response was examined.
Results
Grade 2, or more severe, common adverse events (AEs) included skin rash in 17 patients (35 %), diarrhea in 19 (39 %) and mucositis in 15 (31 %). Of these, the number of patients who developed ≥Grade 2 AEs during the first week after the initiation of afatinib therapy was: five patients had skin rash (10 %), 12 patients had diarrhea (25 %) and four patients had mucositis (8 %). As for an objective response, 21 (43 %) of the 49 had a partial response. Associating the AEs with the antitumor effect, those who had a ≥Grade 2 skin rash within the first week tended to have a greater tumor response compared with those without a rash (80 vs. 39 %;
p
= 0.077).
Conclusion
Our small study demonstrated that the early development of a skin rash might be associated with the response to afatinib monotherapy.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-015-2910-9</identifier><identifier>PMID: 27029623</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Cancer Care Facilities ; Cancer Research ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - metabolism ; Exanthema - chemically induced ; Female ; Humans ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Lung Neoplasms - metabolism ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Mutation ; Oncology ; Original Article ; Pharmacology/Toxicology ; Quinazolines - administration & dosage ; Quinazolines - adverse effects ; Quinazolines - therapeutic use ; Receptor, Epidermal Growth Factor - genetics ; Retrospective Studies ; Time Factors</subject><ispartof>Cancer chemotherapy and pharmacology, 2016-05, Vol.77 (5), p.1005-1009</ispartof><rights>Springer-Verlag Berlin Heidelberg 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-92c5da80e5fcd698ca6727222385193ffc46222170e272006a340d99be76bcb63</citedby><cites>FETCH-LOGICAL-c438t-92c5da80e5fcd698ca6727222385193ffc46222170e272006a340d99be76bcb63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-015-2910-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-015-2910-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27029623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kudo, Kenichiro</creatorcontrib><creatorcontrib>Hotta, Katsuyuki</creatorcontrib><creatorcontrib>Bessho, Akihiro</creatorcontrib><creatorcontrib>Nogami, Naoyuki</creatorcontrib><creatorcontrib>Kozuki, Toshiyuki</creatorcontrib><creatorcontrib>Kuyama, Shoichi</creatorcontrib><creatorcontrib>Inoue, Koji</creatorcontrib><creatorcontrib>Harita, Shingo</creatorcontrib><creatorcontrib>Okada, Toshiaki</creatorcontrib><creatorcontrib>Gemba, Kenichi</creatorcontrib><creatorcontrib>Fujii, Masanori</creatorcontrib><creatorcontrib>Takigawa, Nagio</creatorcontrib><creatorcontrib>Oda, Naohiro</creatorcontrib><creatorcontrib>Tanimoto, Mitsune</creatorcontrib><creatorcontrib>Kiura, Katsuyuki</creatorcontrib><title>Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Background
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are now key agents in treating EGFR-mutant non-small cell lung cancer (NSCLC). The efficacy of gefitinib or erlotinib monotherapy can be predicted by the development of a skin rash. However, it has not been fully evaluated if this is the case with afatinib monotherapy.
Methods
We retrospectively studied 49 consecutive patients with EGFR-mutant NSCLC who received afatinib therapy between 2009 and 2015. The relationship of several toxicities with tumor response was examined.
Results
Grade 2, or more severe, common adverse events (AEs) included skin rash in 17 patients (35 %), diarrhea in 19 (39 %) and mucositis in 15 (31 %). Of these, the number of patients who developed ≥Grade 2 AEs during the first week after the initiation of afatinib therapy was: five patients had skin rash (10 %), 12 patients had diarrhea (25 %) and four patients had mucositis (8 %). As for an objective response, 21 (43 %) of the 49 had a partial response. Associating the AEs with the antitumor effect, those who had a ≥Grade 2 skin rash within the first week tended to have a greater tumor response compared with those without a rash (80 vs. 39 %;
p
= 0.077).
Conclusion
Our small study demonstrated that the early development of a skin rash might be associated with the response to afatinib monotherapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer Care Facilities</subject><subject>Cancer Research</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - metabolism</subject><subject>Exanthema - chemically induced</subject><subject>Female</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - metabolism</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Pharmacology/Toxicology</subject><subject>Quinazolines - administration & dosage</subject><subject>Quinazolines - adverse effects</subject><subject>Quinazolines - therapeutic use</subject><subject>Receptor, Epidermal Growth Factor - genetics</subject><subject>Retrospective Studies</subject><subject>Time Factors</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1UU1v1DAUtBCIbgs_gAuyxAUOhuePfHFDoV2QVlSicI4c57mb7sZJbYeyf6-_DC8piAsH288z82YOQ8gLDm85QPEuAIgSGPCMiYoDqx6RFVdSMCiVfExWIJViWQHqhJyGcAMAikv5lJyIAkSVC7ki9x_xB-7HaUAX6WippmHXO-p12NK7Pm7THLdIbe9DpHeIO6pd9xtKx-sJ59gbitaiiTSJtdWxd31Lh9GNi-RA7ejp-friKxvmqFOOGx0Lg97vqcF07Wd3TY12Bj19_eWq3tRv3tPLnT7oQdPNkawX8irO3YGu_ThPFH9O6HtM-DPyxOp9wOcP7xn5fnH-rf7ENpfrz_WHDTNKlpFVwmSdLgEza7q8Ko3OC1EIIWSZ8Upaa1SefrwATDBArqWCrqpaLPLWtLk8I68W38mPtzOG2NyMs3cpsuFFqVIVUsmk4ovK-DEEj7aZfD9of2g4NMfWmqW1JrXWHFtrqrTz8sF5bgfs_m78qSkJxCIIiXLX6P-J_q_rLwJ4o2c</recordid><startdate>20160501</startdate><enddate>20160501</enddate><creator>Kudo, Kenichiro</creator><creator>Hotta, Katsuyuki</creator><creator>Bessho, Akihiro</creator><creator>Nogami, Naoyuki</creator><creator>Kozuki, Toshiyuki</creator><creator>Kuyama, Shoichi</creator><creator>Inoue, Koji</creator><creator>Harita, Shingo</creator><creator>Okada, Toshiaki</creator><creator>Gemba, Kenichi</creator><creator>Fujii, Masanori</creator><creator>Takigawa, Nagio</creator><creator>Oda, Naohiro</creator><creator>Tanimoto, Mitsune</creator><creator>Kiura, Katsuyuki</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20160501</creationdate><title>Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience</title><author>Kudo, Kenichiro ; Hotta, Katsuyuki ; Bessho, Akihiro ; Nogami, Naoyuki ; Kozuki, Toshiyuki ; Kuyama, Shoichi ; Inoue, Koji ; Harita, Shingo ; Okada, Toshiaki ; Gemba, Kenichi ; Fujii, Masanori ; Takigawa, Nagio ; Oda, Naohiro ; Tanimoto, Mitsune ; Kiura, Katsuyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-92c5da80e5fcd698ca6727222385193ffc46222170e272006a340d99be76bcb63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer Care Facilities</topic><topic>Cancer Research</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - metabolism</topic><topic>Exanthema - chemically induced</topic><topic>Female</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - metabolism</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Pharmacology/Toxicology</topic><topic>Quinazolines - administration & dosage</topic><topic>Quinazolines - adverse effects</topic><topic>Quinazolines - therapeutic use</topic><topic>Receptor, Epidermal Growth Factor - genetics</topic><topic>Retrospective Studies</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kudo, Kenichiro</creatorcontrib><creatorcontrib>Hotta, Katsuyuki</creatorcontrib><creatorcontrib>Bessho, Akihiro</creatorcontrib><creatorcontrib>Nogami, Naoyuki</creatorcontrib><creatorcontrib>Kozuki, Toshiyuki</creatorcontrib><creatorcontrib>Kuyama, Shoichi</creatorcontrib><creatorcontrib>Inoue, Koji</creatorcontrib><creatorcontrib>Harita, Shingo</creatorcontrib><creatorcontrib>Okada, Toshiaki</creatorcontrib><creatorcontrib>Gemba, Kenichi</creatorcontrib><creatorcontrib>Fujii, Masanori</creatorcontrib><creatorcontrib>Takigawa, Nagio</creatorcontrib><creatorcontrib>Oda, Naohiro</creatorcontrib><creatorcontrib>Tanimoto, Mitsune</creatorcontrib><creatorcontrib>Kiura, Katsuyuki</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kudo, Kenichiro</au><au>Hotta, Katsuyuki</au><au>Bessho, Akihiro</au><au>Nogami, Naoyuki</au><au>Kozuki, Toshiyuki</au><au>Kuyama, Shoichi</au><au>Inoue, Koji</au><au>Harita, Shingo</au><au>Okada, Toshiaki</au><au>Gemba, Kenichi</au><au>Fujii, Masanori</au><au>Takigawa, Nagio</au><au>Oda, Naohiro</au><au>Tanimoto, Mitsune</au><au>Kiura, Katsuyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2016-05-01</date><risdate>2016</risdate><volume>77</volume><issue>5</issue><spage>1005</spage><epage>1009</epage><pages>1005-1009</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><abstract>Background
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are now key agents in treating EGFR-mutant non-small cell lung cancer (NSCLC). The efficacy of gefitinib or erlotinib monotherapy can be predicted by the development of a skin rash. However, it has not been fully evaluated if this is the case with afatinib monotherapy.
Methods
We retrospectively studied 49 consecutive patients with EGFR-mutant NSCLC who received afatinib therapy between 2009 and 2015. The relationship of several toxicities with tumor response was examined.
Results
Grade 2, or more severe, common adverse events (AEs) included skin rash in 17 patients (35 %), diarrhea in 19 (39 %) and mucositis in 15 (31 %). Of these, the number of patients who developed ≥Grade 2 AEs during the first week after the initiation of afatinib therapy was: five patients had skin rash (10 %), 12 patients had diarrhea (25 %) and four patients had mucositis (8 %). As for an objective response, 21 (43 %) of the 49 had a partial response. Associating the AEs with the antitumor effect, those who had a ≥Grade 2 skin rash within the first week tended to have a greater tumor response compared with those without a rash (80 vs. 39 %;
p
= 0.077).
Conclusion
Our small study demonstrated that the early development of a skin rash might be associated with the response to afatinib monotherapy.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>27029623</pmid><doi>10.1007/s00280-015-2910-9</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2016-05, Vol.77 (5), p.1005-1009 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_journals_1784028343 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer Care Facilities Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Exanthema - chemically induced Female Humans Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - metabolism Male Medicine Medicine & Public Health Middle Aged Mutation Oncology Original Article Pharmacology/Toxicology Quinazolines - administration & dosage Quinazolines - adverse effects Quinazolines - therapeutic use Receptor, Epidermal Growth Factor - genetics Retrospective Studies Time Factors |
| title | Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T17%3A17%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20a%20skin%20rash%20within%20the%20first%20week%20and%20the%20therapeutic%20effect%20in%20afatinib%20monotherapy%20for%20EGFR-mutant%20non-small%20cell%20lung%20cancer%20(NSCLC):%20Okayama%20Lung%20Cancer%20Study%20Group%20experience&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Kudo,%20Kenichiro&rft.date=2016-05-01&rft.volume=77&rft.issue=5&rft.spage=1005&rft.epage=1009&rft.pages=1005-1009&rft.issn=0344-5704&rft.eissn=1432-0843&rft_id=info:doi/10.1007/s00280-015-2910-9&rft_dat=%3Cproquest_cross%3E4034495621%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1784028343&rft_id=info:pmid/27029623&rfr_iscdi=true |